secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-073945
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health presents preclinical data for RJVA-001 gene therapy; CTA submission expected June 2025
--------------------------------------------------------------------------------

- Single dose RJVA-001 in db/db mice reduced fasting blood sugar >200 mg/dL, increased fasting insulin >2-fold, prevented weight gain.
- Systemic GLP-1 levels 10-20 pM, >5-fold lower than pharmacologic GLP-1 drugs (50-150 pM), potentially reducing side effects.
- Nutrient-responsive GLP-1 secretion demonstrated in human beta cells and islets, mimicking natural hormone regulation.
- Endoscopic ultrasound delivery in pigs achieved targeted pancreatic expression in <20 min with no observed toxicity.
- First CTA module submission for RJVA-001 expected by June 2025; preliminary human data anticipated in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025073945/0000950170-25-073945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025073945/guts-20250517.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-073945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer